BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Fluoxetine
,
rs4950928
,
ERBB2
,
glucose metabolic process
,
Allergy to pollen
,
Lung
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PHA-848125
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
KRCC1
PPP1R10
DKK1
SNX32
HIST2H2BE
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
heterocycle metabolic process
heterocyclic compound binding
nucleoplasm
cellular aromatic compound metabolic process
organic cyclic compound binding
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Multiple myeloma NCI-H929 and JJN3 cells treated with THZ1
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Clival chordoma UM-Chor1 cells treated with THZ1 or actinomycin D
Explore Curated Studies Results
Literature
Most Relevant Literature
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the bloo…
Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the c…
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas s…
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an …
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcino…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for PHA-848125
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ